Clinical trials: Stem Cell Transplants
Hematopoietic Stem Cell Transplant, CAR-T Cell Therapy
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
The aim of this study is to test the efficacy of a hybrid in-person and mHealth coping skills training and activity coaching intervention (Step Up), to enable HCT patients to effectively cope with symptoms (pain, fatigue, and…
- Trial name
- NCT06575712
- Testing
- Step Up, Usual Care Plus (UC+)
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Duke University
Core Binding Factor Alpha Subunits, Hematologic Neoplasms
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Background: Some blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with.
- Conditions
- Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
- Trial name
- NCT07524530
- Testing
- Cyclophosphamide, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Cancer Institute (NCI)
T Cell Non-Hodgkin Lymphoma
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.
- Trial name
- NCT01908777
- Testing
- High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematopoietic Stem Cell Transplantation, Graft Failure
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft…
- Trial name
- NCT07244419
- Testing
- Emapalumab 3 mg/kg, Emapalumab 10 mg/kg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with Relapsed/Refractory DLBCL and iNHL Who are…
- Trial name
- SWATCH (NCT05265975)
- Testing
- ATG-010, Lenalidomide, Rituximab
- Where
- 6 sites in China
- Volunteers
- 54 people
- Sponsor
- Antengene Corporation
Cytokine Release Syndrome, Stem Cell Transplant Complications
Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation
Tocilizumab will be administered prior to transplantation in order to prevent the onset of cytokine release syndrome and its complications associated to peripheral blood haploidentical hematopoietic stem cell transplantation with…
- Trial name
- NCT03533101
- Testing
- Tocilizumab
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Leukemia, Medulloblastoma
Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant
The purpose of this study is to conduct an analysis of the influences of 1. conventional chemotherapy 2. high-dose chemotherapy followed by autologous stem cell transplant 3.
- Trial name
- NCT00231712
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Julius-Maximilians University
Hematopoietic Stem Cell Transplant
Light Therapy to Treat Depression in Pediatric Stem Cell Therapy Recipients
The participants are being asked to be in this clinical trial, a type of research study, because the participants are going to have a hematopoietic stem cell transplant (HSCT) in the near future.
- Trial name
- NCT06496477
- Testing
- Ayo wearable
- Where
- United States
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia (AML)
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML
The purpose of this prospective phase III, open-label, randomized multicenter study is to evaluate whether Acute Myeloid Leukemia (AML) elderly patients in Complete Remission (CR) undergoing allogeneic hematopoietic stem cell…
- Trial name
- GITMO-AMLR2 (NCT01191957)
- Testing
- Busulphan plus Cyclophosphamide, Busulphan plus Fludarabine
- Where
- 26 sites in Israel, Italy
- Volunteers
- 252 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Breast Cancer, Chronic Myeloproliferative Disorders
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
RATIONALE: Alemtuzumab and glucocorticoids, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00410657
- Testing
- alemtuzumab, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Bone Marrow Transplant Complications, Hematologic Malignancy
Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant
The goal of this research study is to determine whether a self-administered, psychosocial mobile application (CARE app) is effective at improving the quality of life and experience of caregivers of patients receiving…
- Trial name
- NCT05709912
- Testing
- CARE Application, Usual Care
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Lymphoma
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00085449
- Testing
- alemtuzumab, cyclosporine, fludarabine phosphate
- Where
- 24 sites in United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
Velcade (Bortezomib) Consolidation After Transplant
The purpose of this study is to determine if bortezomib when added to consolidation treatment with thalidomide and prednisolone leads to an improved response in patients with multiple myeloma who have undergone autologous stem…
- Trial name
- VCAT (NCT01539083)
- Testing
- Thalidomide, Bortezomib, Cyclophosphamide
- Where
- 23 sites in Australia, China and 1 more
- Volunteers
- 256 people
- Sponsor
- Janssen Scientific Affairs, LLC
Hematopoietic Malignancies
Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft
This is an open label phase II single arm study of peripheral blood stem cell transplantation and posttransplantation cyclophosphamide, using HLA full match or haploidentical related donors, in hematological malignancies…
- Trial name
- NCT03187756
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Hematopoietic Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic
Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Before considering high-GVHD Negative Outcome Score (GNOS) donor selection for routine clinical practice, this blinded prospective study will be carried out for assessment of severe GVHD (graft-versus-host-disease) reduction…
- Conditions
- Hematopoietic Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic, Transplantation, Hematopoietic Stem Cell
- Trial name
- NCT02414113
- Where
- 4 sites in United States
- Volunteers
- 113 people
- Sponsor
- Washington University School of Medicine
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery
The goal of this project is to conduct a pilot randomized clinical trial (RCT) to evaluate the feasibility of a brief, behavioral intervention to improve recovery following hematopoietic stem cell transplantation (HSCT).
- Conditions
- Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Lymphoid Leukemia
- Trial name
- NCT02955043
- Testing
- Behavioral techniques
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Wisconsin, Madison
Ischemic Stroke, Ischaemic Cerebral Infarction
Study of Purified Umbilical Cord Blood CD34+ Stem Cell on Chronic Ischemic Stroke
The purpose of the study is to determine the safety and possible effectiveness of brain transplants of CD34+ stem cells obtained from umbilical cord blood (UCB) to treat stroke.
- Conditions
- Ischemic Stroke, Ischaemic Cerebral Infarction, Infarction, Middle Cerebral Artery, Ischemia
- Trial name
- NCT01438593
- Testing
- Intercerebral implantation of allogenic CD34+ stem cell
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- China Medical University Hospital
Acute Myeloid Leukemia
Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT
This trial is a no profit, prospective, phase II, multicentre, non-randomised, uncontrolled, single group assignment, open label study to evaluate the safety and efficacy of the "chemo-free" combination Venetoclax plus Decitabine…
- Trial name
- NCT04476199
- Testing
- Venetoclax and Decitabine
- Where
- 25 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Mantle Cell Lymphoma
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
This study is being done to understand how to treat Mantle Cell Lymphoma (MCL). The goals of treatment are to control the lymphoma with the least amount of side effects.
- Trial name
- NCT01437709
- Testing
- Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center